Improve the safety and effectiveness of medication use in children.
The Division of Translational Therapeutics is uniquely situated in its ability to provide paediatric care at BC Children’s Hospital site where basic science research, clinical research and clinical practice converge. This is crucial to the division, as one of our priorities is to successfully bridge the gap between research and clinical practice in order to smoothly translate innovative/next generation tools, therapies and technologies from the research setting into accepted clinical practice. The bedside-to-bench-to-bedside approach we take is especially important within the context of paediatrics because we know less about how children will respond to medication and treatment, than we do about adult populations suffering from similar medical conditions.
• Teaching colleagues, fellows, residents and students about optimizing drug use in children.
• Providing cutting-edge research that is purpose-built to improve the optimal use of drugs in children using pharmacogenomic, epidemiological and clinical trial methods.
• Providing clinical service to general paediatrics and subspecialties aimed at finding solutions to drug-related problems.
UPDATED JULY 28 2020
We are committed to studying and evaluating drug therapies with the goal of improving human health and quality of life, specifically in the areas of drug effectiveness, drug safety and drug policy. We pursue these goals through:
Population Therapeutics and Pharmacoepidemiology – where we focus on medication use and healthcare outcomes using large scale population based data sets to foster pharmaceutical policy innovation through proactive policy, research and knowledge translation concerning the effectiveness, safety and cost management of prescription drugs.
Advanced Methodologies to Discover Effectiveness – Randomized controlled trials, retrospective studies and combination of qualitative and quantitative methods to discover effectiveness of treatments, mostly in acute care paediatrics.
Adverse drug reactions (ADRs) and Pharmacogenomics – using state of the art genotyping and sequencing platforms we identify the genetic determinants of ADRs in paediatric and adult populations. Through our active surveillance approach we are able to collect cases and controls to conduct genetic association and validation studies to define ADR causal genes and to develop diagnostic tests to offer personalized therapeutic recommendations for commonly used drugs.
Dr. Bruce Carleton is the Director of the Pharmaceutical Outcomes Programme (POPi), Director of the PHSA Therapeutic Evaluation Unit, and CEO of the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). He currently leads numerous multi-disciplinary projects relating to drug safety and drug effectiveness. Details regarding these projects can be found here.
Dr. Ran Goldman is the director of Paediatric Research in Emergency Therapeutics (PRETx), which offers an extensive online database of therapeutics research in paediatric acute care. Details regarding PRETx can be found here.
Dr. Mahyar Etminan is a drug safety researcher. He uses large administrative databases and epidemiologic methodologies to quantify rare adverse drug events. Currently, Dr. Etminan is leading a project examining the cardiovascular outcomes of Avastin and Lucentis, two drug therapies used for the treatment of macular degeneration.
Dr. Colin Ross is working to develop safer and more effective medications. A key area of Dr. Ross’s research is focused on the identification of genetic factors that are responsible for individual differences in susceptibility to severe adverse drug reactions in children. Dr. Ross directs a research laboratory with capacity for genomic analyses, including genome sequencing, and functional studies of the effects of genetic variation on drug response.
Do you want to make a difference in paediatrics? If being part of a multi-disciplinary team that pursues excellence in research, and strives to bridge into clinical practice and educational endeavours through innovative strategies, the division of translation therapeutics is the place you want to be.
The Division of Translational Therapeutics is always seeking excellent Graduate Students (M.Sc. & Ph.D.), Post Doctoral Fellows, Clinical Residents and Fellows who are interested in the areas of population therapeutics, pharmacoepidemiology, adverse drug reactions (ADRs) and pharmacogenomics. Training opportunities can be tailored according to needs – ranging from full-time to part-time activities over the course of time required for the research project in question. Trainees are encouraged to contact us with an area of interest or pre-determined projects to pursue with the input and guidance of the division members. All research projects will include participation in grant and protocol development, ethics application submission, publication of manuscripts, presentation of findings, and knowledge translation planning.
As one of the leading research centers in Canada, trainees will be exposed to both the innovative research at BC Children’s Hospital Research Institute and the strong academic environment of the University of British Columbia. In these stimulating and complementary surroundings, trainees will have many opportunities for advancement and interdisciplinary professional development.
Applicants with a background in pharmacogenomics, clinical pharmacology, medical genetics, experimental medicine, paediatrics, pharmacoepidemiology, biostatistics, population health, pharmacy, medical anthropology, ethics or any other related fields are encouraged to contact us.
The Division of Translational Therapeutics provides consultation services to their colleagues at UBC and PHSA affiliated institutions, including: BC Children’s Hospital, Sunny Hill Health Centre, Women’s Hospital, BC Cancer Agency and Vancouver General Hospital. These consultations are primarily complex patient cases addressing drug therapies and/or associated adverse drug reactions (ADRs). In cases where appropriate, the division can provide genotyping and interpretation to provide additional information with regards to therapeutic decisions.
1. Virani AK, Puls HT, Mitsos R, Longstaff H, Goldman RD, Lantos JD. Benefits and Risks of Visitor Restrictions for Hospitalized Children During the COVID Pandemic [published online ahead of print, 2020 May 19]. Pediatrics. 2020;e2020000786. doi:10.1542/peds.2020-000786
2. Ratnarajah K, Clarke AE, McCusker C, et al. Anaphylaxis as a presenting symptom of food allergy in children with no known food allergy [published online ahead of print, 2020 Apr 26]. J Allergy Clin Immunol Pract. 2020;S2213-2198(20)30385-8. doi:10.1016/j.jaip.2020.04.033
3. Goldman RD, Long KC, Brown JC. Hooked epinephrine auto-injector devices in children: four case reports with three different proposed mechanisms. Allergy Asthma Clin Immunol. 2020;16:19. Published 2020 Mar 14. doi:10.1186/s13223-020-00418-0
4. Goldman RD, Kong C, Henkelman E. Organic facial foreign body in a ski accident: Case report and review of the literature [published online ahead of print, 2020 Jun 25]. J Paediatr Child Health. 2020;10.1111/jpc.14966. doi:10.1111/jpc.14966
5. Yan T, Goldman RD. Melatonin for children with autism spectrum disorder. Can Fam Physician. 2020;66(3):183-185.
6. Ogilvie-Turner K, Goldman RD. Cantharidin for molluscum contagiosum. Can Fam Physician. 2020;66(6):419-420.
7. Fernando T, Goldman RD. Management of gastroesophageal reflux disease in pediatric patients with cerebral palsy. Can Fam Physician. 2019 Nov;65(11):796-798.
8. Yan T, Goldman RD. Time-to-effect of fluoxetine in children with depression. Can Fam Physician. 2019 Aug;65(8):549-551.
9. Matettore A, Rajaprakash M, Bennett M, Skarsgard ED, Goldman RD. Abdominal Tuberculosis in an Infant Presenting With a Small Bowel Obstruction. Pediatr Emerg Care. 2019 Jul 5.
10. Yamanaka S, Goldman RD, Goto T, Hayashi H. Multiple intubation attempts in the emergency department and in-hospital mortality: A retrospective observational study. Am J Emerg Med. 2019 Jun 20.
11. Yodoshi T, Ueda S, Goldman RD. Skin preparation for prevention of peripheral blood culture contamination in children. Pediatr Int. 2019 Jul;61(7):647-651.
12. Goldman RD. Duct tape for warts in children: Should nature take its course? Can Fam Physician. 2019 May;65(5):337-338.
13. Goldman RD. Raynaud phenomenon in children. Can Fam Physician. 2019 Apr;65(4):264-265.
14. Goldman RD. The pain of procedural pain management education in the emergency department. CJEM. 2019 Mar;21(2):161-162.
15. Goldman RD. Analgesia for lumbar puncture in infants and children. Can Fam Physician. 2019 Mar;65(3):192-194.
16. Doan Q, Goldman RD, Meckler GD. Management practice-related and modifiable factors associated with paediatric emergency return visits. Paediatr Child Health. 2019 Feb;24(1):e1-e7.
17. Khalifa I, Goldman RD. Anorexia nervosa requiring admission in adolescents. Can Fam Physician. 2019 Feb;65(2):107-108.
1. Loucks C, Groeneweg G, Roy C, Lee DK, Rieder MJ, Lebel D, Ito S, Ross CJ, Carleton BC. Pharmacogenomic testing: the key to enhancing personalized medication use for patients. Can Fam Physician. 2020 Apr;66(4):241-243. PMID: 32273406
2. Takeuchi M, Kobayashi T, Biss T, Kamali F, Vear SI, Ho RH, Bajolle F, Loriot MA, Shaw K, Carleton BC, Hamberg AK, Wadelius M, Hirono K, Taguchi M, Wakamiya T, Yanagimachi M, Hirai K, Itoh K, Brandão LR, Ito S. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. Pharmacogenomics J. 2020 Apr;20(2):306-319. PMID: 31673144
3. Chang W, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky TM, Bellón T, Biala AK, Bouchard C, Cavalleri GL, Chapman N, Chodosh J, Choi HK, Cibotti RR, Divito SJ, Dewar K, Dehaeck U, Etminan M, Forbes D, Fuchs E, Goldman JL, Holmes JH, Hope EA, Hung S, Hsieh C, Iovieno A, Jagdeo J, Kim MK, Koelle DM, Lacouture ME, Le Pallec S, Lehloenya RJ, Lim R, Lowe A, McCawley J, McCawley J, Micheletti RG, Mockenhaupt M, Niemeyer K, Norcross MA, Oboh D, Olteanu C, Pasieka HB, Peter J, Pirmohamed M, Rieder M, Saeed HN, Shear NH, Shieh C, Straus S, Sukasem C, Sung C, Trubiano JA, Tsou S, Ueta M, Volpi S, Wan C, Wang H, Wang Z, Weintraub J, Whale C, Wheatley LM, Whyte-Croasdaile S, Williams KB, Wright G, Yeung SN, Zhou L, Chung W, Phillips EJ, Carleton BC. SJS/TEN 2019: From Science to Translation. J Dermatol Sci. 2020 Mar 7:S0923-1811(20)30064-5. PMID: 32192826
4. Lasky T, Carleton B, Horton DB, Kelly LE, Bennett D, Czaja AS, Gifkins D, Osokogu OU, McMahon AW. Real-world Evidence to Assess Medication Safety and Effectiveness in Children: Systematic Review. Drugs Real World Outcomes, 2020 Feb 28. PMID: 32112359
5. McMahon AW, Cooper WO, Brown JS, Carleton B, Doshi-Velez F, Kohane I, Goldman JL, Hoffman MA, Kamaleswaran R, Sakiyama M, Sekine S, Sturkenboom MC, Turner MA, Califf RM. Big Data in the Assessment of Pediatric Medication Safety. Pediatrics. 2020 Feb;145(2):e20190562. PMID: 31937606
6. Sodhi M, Etminan M, Carleton B, Samii A. Risk of Pathological Gambling and Impulse Control Disorders With Dopamine Agonists: A Retrospective Cohort Study. J Clin Psychopharmacol. 2019 Nov/Dec;39(6):675-676. PMID: 31688453
7. Etminan M, Sodhi M, Ganjizadeh-Zavareh S, Carleton B, Kezouh A, Brophy JM. Oral Fluoroquinolones and Risk of Mitral and Aortic Regurgitation. J Am Coll Cardiol. 2019 Sep;74(11):1444-1450 PMID: 31514945
8. Drögemöller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, Rassekh SR, Ross CJD, Carleton BC. Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings and Future Avenues of Research. Clin Pharm Ther. 2019 Aug;106(2):350-359 PMID: 31012503
9. Zazuli Z, Otten LS, Drögemöller BI, Medeiros M, Monzon JG, Wright GEB, Kollmannsberger CK, Bedard PL, Chen Z, Gelmon KA, McGoldrick N, Kitchlu A, Vijverberg SJH, Masereeuw R, Ross CJD, Liu G, Carleton BC, Maitland-van der Zee AH. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. Genes. 2019 May;10(5):364. PMID: 31083486
10. Tanoshima R, Khan A, Biala AK, Trueman JN, Drögemöller BI, Wright GEB, Hasbullah JS, Groeneweg GSS, Ross CJD, Carleton BC. Analyses of Adverse Drug Reactions Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety (CPNDS) database. J Clin Pharmacol. 2019 Mar;59(3):356-363. PMID: 30452777
11. Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink M, Carleton B. A Comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAE v4.03 Ototoxicity Grading Scales Applied to 3,799 Audiograms of Childhood Cancer Patients Treated with Platinum-Based Chemotherapy. PLOS ONE. 2019 Feb 14;14(2):e0210646. PMID: 30763334
12. Drögemöller BI, Wright GEB, Shih J, Monzon J, Gelmon KA, Ross CJD, Amstutz U, Carleton BC on behalf of the CPNDS Clinical Recommendations Group. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast Cancer Res Treat. 2019 Feb;173(3):521-532. PMID: 30411242
13. Wright GEB, Amstutz U, Drögemöller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC, Ross CJD, the Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2019 Feb;105(2):402-410. PMID: 29999516
14. Chau CMY, Ross CJD, Chau V, Synnes AR, Miller SP, Carleton BC, Grunau RE. Morphine Biotransformation Genes and Neonatal Clinical Factors Predicted Behaviour Problems in Very Preterm Children at 18 Months. EBioMedicine. 2019 Feb;40:655-662. PMID:30709768
15. Mansouri M, Yuan B, Ross CJD, Carleton BC, Ester M. HUME: Large-scale Detection of Causal Genetic Factors of Adverse Drug Reactions. Bioinformatics. 2018 Dec 15;34(24):4274-4283. PMID: 29931042
1. Mukonzo J, Owen J, Ogwal-Okeng J, Kuteesa, R, Nanzigu S, Sewankambo N, Thabane L, Gustafsson L, Ross CJD, Aklillu E. Pharmacogenetic based Efavirenz dose modification: Suggestions for an African population and the different CYP2B6 genotypes. PLOS ONE. 2014 Jan 31;9(1)e86919.
2. Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Hayden MR, Ross CJD, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Paediatric Blood & Cancer. 2014 Jun;61(6):1055-62.
3. Lee JW, Aminkeng F, Bhavsar AP, Shaw K, Carleton BC, Hayden MR, Ross CJ. The emerging era of pharmacogenomics: Current successes, future potential, and challenges. Clin Genet. 2014 Jul;86(1):21-8.
4. Visscher H, Ross CJD, Rassekh SR, Sandor G, Caron HN, van Dalen EC, Kremer LC, van der Pal J, Rogers PC, Rieder MJ, Carleton BC, Hayden MR & the CPNDS consortium. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Paediatric Blood & Cancer. 2013 Aug;60(8):1375-81.
5. Pussegoda K, Ross CJD, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Carleton BC, Hayden MR & the CPNDS Consortium. Replication of TPMT genetic variants highly associated with cisplatin-induced hearing loss in children. Clin. Pharmacol & Therapeutics . 2013 Aug; 94(2):243-51.
6. Amstutz U, Ross CJD, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC; CPNDS Consortium. HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013 Jul;94(1):142-9.
7. Sistonen J, Madadi P, Ross CJD, Yazdanpanah M, Lee J, Landsmeer M, Nauta M, Carleton BC, Koren G, Hayden MR. Prediction of opioid toxicity in neonates and their mothers using a novel combination of genetic markers. Clinical Pharmacology & Therapeutics. 2012 Apr;91(4):692-9.
8. Shaw K, Amstutz U, Jimenez-Mendez R, Ross CJD, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Therapeutic Drug Monitoring. 2012 Apr;34(2):121-3.
9. Visscher H, Ross CJD, Rassekh R, Barhdadi A, Dubé MP, al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AMK, Rogers PC, Phillips MS, Rieder M, Carleton BC, Hayden MR, & the CPNDS consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. Journal of Clinical Oncology. 30:1422-1428, 2012.
10. Ross CJD, Visscher H, Rassekh SR, Castro-Pastrana L, Shereck E, Carleton BC, Hayden MR. Pharmacogenomics of serious adverse drug reactions in paediatric oncology. Journal of Population Therapeutics and Clinical Pharmacology. J Popul Ther Clin Pharmacol. 2011;18:e134-51.
11. Ross CJD, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC and Hayden MR and the CPNDS Consortium. The Canadian Pharmacogenomics Network for Drug Safety - A model for safety pharmacology. Thyroid. 2010 Jul;20(7):681-7.
12. Madadi P, Ross CJD, Hayden MR, Carleton BC, Gaedigk A, Leeder JS, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: A case–control study. Clinical Pharmacology & Therapeutics. 2009 Jan;85(1):31-5.
13. Visscher H, Ross CJD, Dubé MP, Carleton B, Hayden MR. Application of principal component analysis to pharmacogenomic studies in Canada. J Pharmacogenomics. 2009 Dec;9(6):362-72.
14. Ross CJD, Katzov-Eckert H, Dubé MP, Brook B, Rassekh SR, Barhdadi A, Feroz-Zadac Y, Visscher H, Brown AMK, Rogers PC, Phillips MS, Carleton B, Hayden MR. TPMT and COMT genetic variants are predictive for severe hearing loss in children receiving cisplatin chemotherapy. Nature Genetics. 41, 1345 - 1349 Dec. 2009.
15. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, Maas MM, Zwinderman AH, Ross CJD, Aronica E, High KA, Levi MM, Hayden MR, Kastelein JJ, Kuivenhoven JA. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol. 2008 Dec;28(12):2303-4.
16. Ross CJD, Carleton B, Warn DG, Stenton SB, Rassekh SR, Hayden MR. Genotypic Approaches to Therapy in Children (GATC): A national active surveillance network to study the pharmacogenomics of severe adverse drug reactions in children. Annals of the New York Academy of Sciences. 1110:177-92. 2007.
17. Ross CJD, Twisk J, Kuivenhoven JA, Rip J, Kastelein JJ, Hayden MR. Gene therapy with Lipoprotein Lipase Variant S447X. Arterioscler Thromb Vasc Biol. 2006;26:25-28.
18. Ross CJD, Twisk J, Meulenberg JJM, Kuivenhoven JA, Miao F, Scheenhart-van der Meer JWC, Moraal E, Oranje PPA, Hermens WTJMC, Kastelein JJP, Hayden MR. Correction of Feline Lipoprotein Lipase Deficiency with AAV1-mediated gene transfer of the naturally-occurring LPLS447X beneficial mutation. Hum Gen Ther 2006;17(5):487-99.
19. Ross CJD, Liu G, Kuivenhoven JA, Twisk J, Rip J, van Dop W, Ashbourne Excoffon KJ, Lewis SM, Kastelein JJ, Hayden MR. Complete Rescue of Lipoprotein Lipase-Deficient Mice by Somatic Gene Transfer of the Naturally Occurring LPLS447X Beneficial Mutation. Arterioscler. Thromb. Vasc. Biol. 25(10):2143-50. October 2005.
20. Ross CJD, Twist J, Meulenberg JJM, Liu G, Van Den Oever K, Moraal E, Hermens WT, Rip J, Kastelein JJP, Kuivenhoven JA, Hayden MR. Long-term correction of murine Lipoprotein Lipase Deficiency with AAV1-mediated gene transfer of the naturally-occurring LPLS447X beneficial mutation. Human Gene Therapy, 15 (9) 906-919, September, 2004. (Cover)
1. Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA. Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 2013 ;185(2):E115-20.
2. Etminan M, Bird ST, Delaney JA, Bressler B, Brophy JM. Isotretinoin and Risk for Inflammatory Bowel Disease: A Nested Case-Control Study and Meta-analysis of Published and Unpublished Data. JAMA Dermatol 2013;149:216-20.
3. Bird ST, Hartzema AG, Etminan M, Brophy JM, Delaney JA. Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. Gynecol Endocrinol 2013
4. Bird ST, Delaney JA, Etminan M, Brophy JM, Hartzema AG. Drospirenone and non-fatal venous thromboembolism: Is there a risk difference by dosage of Ethinyl-Estradiol? J Thromb Haemost 2013
5. Jafari S, Etminan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: A systematic review and meta-analysis. Mov Disord 2013
6. Yang L, Etminan M, Mikelberg FS. Oral Fluoroquinolones and Risk of Glaucoma. J Glaucoma 2013
7. Bird ST, Brophy JM, Hartzema AG, Delaney JA, Etminan M. Male breast cancer and 5-alpha reductase inhibitors, finasteride and dutasteride. J Urol 2013;190:1811-4.
8. Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JA. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ 2013;185:475-82.
9. Pakzad-Vaezi KL, Etminan M, Mikelberg FS. The Association between Cataract Surgery and Atypical Antipsychotic Use: A Nested Case-Control Study. Am J Ophthalmol 2013
10. Forooghian F, Maberley D, Albiani DA, Kirker AW, Merkur AB, Etminan M. Uveitis Risk following Oral Fluoroquinolone Therapy: A Nested Case-control Study. Ocul Immunol Inflamm 2013;21:390-3.
11. Nathoo NA, Etminan M, Mikelberg FS. Association Between Glaucoma, Glaucoma Therapies, and Erectile Dysfunction. J Glaucoma 2013
12. Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ 2013
Faculty and Staff
- Bruce Carleton, PharmD, FCP, FISPE, Division Co-Chair
- Ran Goldman, MD, Division Co-Chair
- Mahyar Etminan, PharmD, MSc
- Colin Ross, MSc, PhD
- Wan-Chun (Kathy) Chang, PhD (Carleton) – Postdoctoral Research Fellow
- Catrina Loucks, MSc, PhD (Carleton) – Postdoctoral Research Fellow
- Erika Scott, BMSc (Ross) – PhD Student
- Eduardo Juárez, MD, MSc (Carleton) – PhD Student
- Jafar Hasbullah, BSc(Hons) (Ross) – PhD Student
- Kevin Yan, BScPharm (Carleton) – PhD Student
- Jennifer Lin, BSc (Carleton) – MSc Student
- Angela Siemens, BSc (Carleton) – MSc Student